

Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C258B46980CEEN.html>

Date: July 2022

Pages: 518

Price: US\$ 2,000.00 (Single User License)

ID: C258B46980CEEN

Abstracts

Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body's organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 29, 12, 1, 76, 42 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 8 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Cystic Fibrosis - Overview

Cystic Fibrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cystic Fibrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cystic Fibrosis - Companies Involved in Therapeutics Development

Cystic Fibrosis - Drug Profiles

(ammonium chloride + citric acid + sodium citrate) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(elixacaftor + ivacaftor + tezacaftor) + ivacaftor - Drug Profile

Product Description

Mechanism Of Action

History of Events

(ethylenediaminetetraacetic acid + sodium nitrite) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(ivacaftor + lumacaftor) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(ivacaftor + tezacaftor + bamocafator potassium) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(ivacaftor + tezacaftor) + ivacaftor - Drug Profile

Product Description
Mechanism Of Action
History of Events
4D-710 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABBV-191 - Drug Profile
Product Description
Mechanism Of Action
ABO-401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACF-516 - Drug Profile
Product Description
Mechanism Of Action
ADDITIONAL SMALL MOLECULES 1 - Drug Profile
Product Description
Mechanism Of Action
AGL-503 - Drug Profile
Product Description
Mechanism Of Action
History of Events
alidornase alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
alpha-1 proteinase inhibitor (human) second generation - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANT-3273 - Drug Profile
Product Description
Mechanism Of Action
APPA-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events

ARCT-032 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ARO-ENaC2 - Drug Profile

Product Description

Mechanism Of Action

ARV-1907 - Drug Profile

Product Description

Mechanism Of Action

ascorbic acid - Drug Profile

Product Description

Mechanism Of Action

History of Events

AT-010 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AvR-2V10 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BBP-321 - Drug Profile

Product Description

Mechanism Of Action

BFP-002 - Drug Profile

Product Description

Mechanism Of Action

BFP-102 - Drug Profile

Product Description

Mechanism Of Action

BI-1323495 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-3720931 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BIOC-51 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BOS-857 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BP-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BrB-102 - Drug Profile

Product Description

Mechanism Of Action

brensocatib - Drug Profile

Product Description

Mechanism Of Action

History of Events

brevenal - Drug Profile

Product Description

Mechanism Of Action

History of Events

BX-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Calcaftor - Drug Profile

Product Description

Mechanism Of Action

History of Events

CAT-5571 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CB-280 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CF-370 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CGT-001 - Drug Profile

Product Description

Mechanism Of Action

CHF-6333 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CMTX-101 - Drug Profile

Product Description

Mechanism Of Action

colistimethate sodium - Drug Profile

Product Description

Mechanism Of Action

CSA-13 - Drug Profile

Product Description

Mechanism Of Action

History of Events

cysteamine - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

dirocaftor - Drug Profile

Product Description

Mechanism Of Action

History of Events

dornase alfa - Drug Profile

Product Description

Mechanism Of Action

Drug for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

Drug to Inhibit SLPI for Asthma and Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

Drugs for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

Drugs to Activate CFTR for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

Drugs to Activate CFTR for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

EBX-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ECP-104 - Drug Profile

Product Description

Mechanism Of Action

EG-i08 - Drug Profile

Product Description

Mechanism Of Action

ELX-02 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ensifentrine - Drug Profile

Product Description

Mechanism Of Action

History of Events

ETD-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ETD-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ETX-001 - Drug Profile

Product Description
Mechanism Of Action
History of Events
EVXB-2 - Drug Profile
Product Description
Mechanism Of Action
fenretinide - Drug Profile
Product Description
Mechanism Of Action
History of Events
FTX-003 - Drug Profile
Product Description
Mechanism Of Action
fusidic acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
galicaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Cystic Fibrosis and Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile

Product Description
Mechanism Of Action
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
heparin sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
HY-006 - Drug Profile
Product Description
Mechanism Of Action
ICL4 Additional Candidates - Drug Profile
Product Description
Mechanism Of Action
ivacaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
KB-407 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KIT-2014 - Drug Profile
Product Description

Mechanism Of Action
History of Events
Iefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
LMS-611 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Isonodelestat - Drug Profile
Product Description
Mechanism Of Action
History of Events
MG-277 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MRT-5005 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
murepavadin - Drug Profile
Product Description
Mechanism Of Action
History of Events
N-115 - Drug Profile
Product Description
Mechanism Of Action
History of Events
nadolol - Drug Profile
Product Description
Mechanism Of Action
History of Events
nafamostat mesylate - Drug Profile

Product Description
Mechanism Of Action
History of Events
NAS-415 - Drug Profile
Product Description
Mechanism Of Action
History of Events
navocafort - Drug Profile
Product Description
Mechanism Of Action
History of Events
NBD1 Additional Candidates - Drug Profile
Product Description
Mechanism Of Action
nesolicaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
niclosamide - Drug Profile
Product Description
Mechanism Of Action
History of Events
NU-8 - Drug Profile
Product Description
Mechanism Of Action
OligoG - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oligonucleotide to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotide to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events

Oligonucleotides to Activate CFTR for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Optate - Drug Profile

Product Description

Mechanism Of Action

ORP-100S - Drug Profile

Product Description

Mechanism Of Action

History of Events

ORP-110 - Drug Profile

Product Description

Mechanism Of Action

OTP-602 - Drug Profile

Product Description

Mechanism Of Action

P-2114 - Drug Profile

Product Description

Mechanism Of Action

P-2176 - Drug Profile

Product Description

Mechanism Of Action

Pemziviptadil - Drug Profile

Product Description

Mechanism Of Action

History of Events

PLG-0301 - Drug Profile

Product Description

Mechanism Of Action

posenacaftor - Drug Profile

Product Description

Mechanism Of Action

History of Events

pravibismane - Drug Profile

Product Description

Mechanism Of Action

History of Events

Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis,

Hospital Acquired Pneumonia and Diabetic Foot Infection - Drug Profile

Product Description

Mechanism Of Action

History of Events

PTINC-733 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RBR-042 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Enzyme to Inhibit DNA for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

renzapride - Drug Profile

Product Description

Mechanism Of Action

History of Events

RP-557 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RSBT-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RTX-0001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RVT-801 - Drug Profile

Product Description

Mechanism Of Action

History of Events

S-1226 - Drug Profile

Product Description

Mechanism Of Action

History of Events

S-1229 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Sanguinate - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBI-001 - Drug Profile

Product Description

Mechanism Of Action

SCB-203 - Drug Profile

Product Description

Mechanism Of Action

seliciclib - Drug Profile

Product Description

Mechanism Of Action

History of Events

SHP-111 - Drug Profile

Product Description

Mechanism Of Action

SHP-636 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SION-109 - Drug Profile

Product Description

Mechanism Of Action

SION-638 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate CFTR for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile

Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Respiratory Diseases - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action

Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Block SCNN1 for Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Penicillin Binding Protein for Gram-Negative Bacterial Infections and Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

SNSP-113 - Drug Profile

Product Description

Mechanism Of Action

History of Events

sodium calcium edetate + tobramycin - Drug Profile

Product Description

Mechanism Of Action

sodium nitrite - Drug Profile

Product Description

Mechanism Of Action

History of Events

SOL-512 - Drug Profile

Product Description

Mechanism Of Action

SPIRO-2101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SPIRO-2102 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SPIRO-2110 - Drug Profile

Product Description

Mechanism Of Action
SPL-16 - Drug Profile
Product Description
Mechanism Of Action
SPL-232 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SPL-24N - Drug Profile
Product Description
Mechanism Of Action
SPL-5A - Drug Profile
Product Description
Mechanism Of Action
SPL-5B - Drug Profile
Product Description
Mechanism Of Action
History of Events
SPL-8423 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SRI-41315 - Drug Profile
Product Description
Mechanism Of Action
SYD-0073 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYGN-303 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TA-270 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAVT-135 - Drug Profile
Product Description

Mechanism Of Action
teicoplanin - Drug Profile
Product Description
Mechanism Of Action
History of Events
thymalfasin - Drug Profile
Product Description
Mechanism Of Action
thymalfasin - Drug Profile
Product Description
Mechanism Of Action
TMD1 Candidates - Drug Profile
Product Description
Mechanism Of Action
tobramycin - Drug Profile
Product Description
Mechanism Of Action
tobramycin - Drug Profile
Product Description
Mechanism Of Action
History of Events
tobramycin + triclosan - Drug Profile
Product Description
Mechanism Of Action
History of Events
trimethylangelicin - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-009 - Drug Profile
Product Description
Mechanism Of Action
VX-121 + deutivacaftor + tezacaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
VX-551 - Drug Profile
Product Description
Mechanism Of Action

History of Events

VXc-0522 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VXc-522 - Drug Profile

Product Description

Mechanism Of Action

History of Events

XF-70 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YPT-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

zelpultide alfa - Drug Profile

Product Description

Mechanism Of Action

Cystic Fibrosis - Dormant Projects

Cystic Fibrosis - Discontinued Products

Cystic Fibrosis - Product Development Milestones

Featured News & Press Releases

Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound

Jul 07, 2022: Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for public reimbursement of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children With cystic fibrosis ages 6 and older

Jun 11, 2022: Vertex to present data demonstrating significant benefits of long-term and early treatment With CFTR modulators at the European Cystic Fibrosis Conference

May 18, 2022: Recode therapeutics presents new preclinical data from mRNA-based program for cystic fibrosis at the ATS 2022 International Conference

Apr 21, 2022: Health Canada approves Vertex's Trikafta for cystic fibrosis in children

Apr 18, 2022: ContraFect announces multiple presentations of new data demonstrating the potential of its Direct Lytic Agent CF-370 to address antimicrobial resistance at the 32nd Annual ECCMID Meeting

Apr 12, 2022: Entrinsic Bioscience steps closer to amino acid formulation as therapy for cystic fibrosis

Apr 11, 2022: Nabriva Therapeutics announces first patient enrolled in phase 1 trial of XENLETA (Iefamulin) in adult patients with cystic fibrosis

Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine

Mar 29, 2022: Eloxx Pharmaceuticals announces therapeutic development Award from Cystic Fibrosis Foundation

Mar 26, 2022: Vertex announces reimbursement agreement in Australia for TRIKAFTA (Ilexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients With cystic fibrosis ages 12 years and older with at least one F508del mutation in the CFTR gene

Mar 25, 2022: Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H Mutation in the CFTR Gene

Jan 12, 2022: EC approves Vertex's combination therapy for cystic fibrosis in children

Jan 05, 2022: SpliSense announces FDA and EMA grant Orphan Drug Designation to SPL84-23-1 for the treatment of cystic fibrosis

Jan 05, 2022: Peptilomics receives award from the Cystic Fibrosis Foundation to investigate PLG0301 as potential dual-acting treatments for lung infections associated with cystic fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cystic Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cystic Fibrosis - Dormant Projects, 2022
Cystic Fibrosis - Discontinued Products, 2022
Cystic Fibrosis - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cystic Fibrosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C258B46980CEEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C258B46980CEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

